'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update

New details are emerging in the lawsuit against Bristol Myers Squibb over a scuppered Contingent Value Rights (CVR) payout tethered to its $74 billion Celgene takeover.

Former Celgene shareholders filed suit against BMS back in June, accusing the drugmaker of “blatant misconduct” in allegedly delaying development of CAR-T lymphoma therapy Breyanzi. At the time of the original filing, BMS declined to comment.